SEC Form 4 · accession 0001996255-26-000004
Estrella Immunopharma, Inc. · ESLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cheng Liu
Officer — CEO · Director
Period of report
Aug 25, 2026
Accepted (ET)
Aug 26, 2026 · 7:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001844417
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1,F2 | Aug 25, 2026 | M | 100,000 | $0.815 | A | 397,437 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock OptionF3,F4 | $0.815 | Aug 25, 2026 | M | 100,000 | A | Oct 31, 2024 | Oct 29, 2034 | Common Stock | 100,000 | 900,000 | D |
Explanation of responses
- F1Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.
- F2Reflects the 297,437 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.
- F3Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.
- F4Not applicable. The reported transaction is the exercise of the stock option for the exercise price set forth in Column 2. No separate consideration was paid or received for the derivative security.